Search - tctmd.com

Displaying 561 - 580 of 764

Sort: Relevancy | Date

News Daily News

Las Noticias Más Leídas del “Top 10” de TCTMD en 2012

Jason Kahn

January 02, 2013

News Industry News

Abbott Announces FDA Approval and U.S. Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent System

January 02, 2013

News Daily News

EES Outperform First-Generation DES in Treatment of CTOs

L.A. McKeown

December 27, 2012

News Daily News

Real-World Equivalence Seen for Zotarolimus- and Everolimus-Eluting Stents

Caitlin E. Cox

December 26, 2012

News Daily News

Equivalencia en el Mundo Real Confirmada de los Stents liberadores de Zotarolimus y Everolimus

Caitlin E. Cox

December 26, 2012

Presentation

Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V vs. Zotarolimus-Eluting Resolute Stents in Real-World Practice

Presenter: K. W. Park

December 25, 2012

News Industry News

First Patient Enrolled in the Boston Scientific Multicenter Study of the SYNERGY™ Coronary Stent System Featuring a Bioabsorbable Polymer Coating

November 29, 2012

News Conference News TCT 2012

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

November 02, 2012

News Conference News TCT 2012

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

October 31, 2012

News Industry News

Boston Scientific Receives CE Mark Approval for the SYNERGY™ Everolimus-Eluting Platinum Chromium Coronary Stent System, Featuring A Novel Bioabsorbable Polymer Coating

October 31, 2012

Presentation TCT 2012

XIMA: A Prospective, Randomized Trial of Everolimus-Eluting Stents vs. Bare-Metal Stents in Octogenarians

Presenter: Adam de Belder

October 26, 2012

News Conference News TCT 2012

No Excess Bleeding with EES vs. BMS in Octogenarians Despite Prolonged DAPT

October 26, 2012

Presentation TCT 2012

TWENTE 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents

Presenter: Clemens von Birgelen

October 25, 2012

Presentation TCT 2012

SEDUCE: A Prospective, Randomized Trial of Drug Coated Balloon vs. Everolimus-Eluting Stent in for BMS Restenosis: Optical Coherence Tomography Assessment

Presenter: Tom Adriaenssens

October 25, 2012

Presentation TCT 2012

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Ken Kozuma

October 25, 2012

Presentation TCT 2012

Long-Term Results of Bifurcation Stenting with Everolimus-eluting vs. Sirolimus-eluting Stents: The SEA-CORP BC Trials

Presenter: Francesco Burzotta

October 25, 2012

Presentation TCT 2012

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Lisette Okkels Jensen

October 25, 2012

Presentation TCT 2012

EXAMINATION 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Bare Metal Stents in Patients with ST-Segment Elevation Myocardial Infarction

Presenter: Manel Sabate

October 25, 2012

Presentation TCT 2012

ISAR-LEFT MAIN 2: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents in Patients with Unprotected Left Main Disease

Presenter: Julinda Mehilli

October 24, 2012

News Industry News

Second Generation Drug-Eluting Stents are Safe and Effective in Treatment of Left Main Coronary Artery Disease

October 24, 2012

Advertisement

Las Noticias Más Leídas del “Top 10” de TCTMD en 2012

Abbott Announces FDA Approval and U.S. Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent System

EES Outperform First-Generation DES in Treatment of CTOs

Real-World Equivalence Seen for Zotarolimus- and Everolimus-Eluting Stents

Equivalencia en el Mundo Real Confirmada de los Stents liberadores de Zotarolimus y Everolimus

Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V vs. Zotarolimus-Eluting Resolute Stents in Real-World Practice

First Patient Enrolled in the Boston Scientific Multicenter Study of the SYNERGY™ Coronary Stent System Featuring a Bioabsorbable Polymer Coating

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

Boston Scientific Receives CE Mark Approval for the SYNERGY™ Everolimus-Eluting Platinum Chromium Coronary Stent System, Featuring A Novel Bioabsorbable Polymer Coating

XIMA: A Prospective, Randomized Trial of Everolimus-Eluting Stents vs. Bare-Metal Stents in Octogenarians

No Excess Bleeding with EES vs. BMS in Octogenarians Despite Prolonged DAPT

TWENTE 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents

SEDUCE: A Prospective, Randomized Trial of Drug Coated Balloon vs. Everolimus-Eluting Stent in for BMS Restenosis: Optical Coherence Tomography Assessment

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Long-Term Results of Bifurcation Stenting with Everolimus-eluting vs. Sirolimus-eluting Stents: The SEA-CORP BC Trials

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

EXAMINATION 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Bare Metal Stents in Patients with ST-Segment Elevation Myocardial Infarction

ISAR-LEFT MAIN 2: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents in Patients with Unprotected Left Main Disease

Second Generation Drug-Eluting Stents are Safe and Effective in Treatment of Left Main Coronary Artery Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content